Resistant hypertension increases stroke risk by 20% in elderly and 35% in women
Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan.
The findings suggest that gender and age should be added to the risk stratification of resistant hypertension to enable more appropriate treatment decisions.
Hypertension is one of the most important risk factors for cardiovascular disease. Patients with hypertension that does not respond to conventional drug treatments, called resistant hypertension, are at even higher risk of cardiovascular morbidity and mortality.
Little is known about the prognosis of resistant hypertension in the Asian population. The study compared the risk of all-cause mortality, acute coronary syndrome, and stroke between patients with resistant hypertension and non-resistant hypertension.
The researchers’aim was to discover the impact of resistant hypertension on Taiwanese patients, and to ascertain whether patient characteristics influence the association between resistant hypertension and adverse outcomes.
Patients with hypertension aged 45 years and older were identified from the National Health Insurance Research Database. Medical records of 111,986 patients from 2000 to 2011 were reviewed for this study. Some 16,402 ( 14.6% ) patients had resistant hypertension ( defined as continuously concomitant use of three or more anti-hypertensive medications, including a diuretic, for 2 years or longer ).
The risk of major adverse cardiovascular events ( MACE; a composite of all-cause mortality, acute coronary syndrome, and stroke ) in patients with resistant hypertension and non-resistant hypertension was analysed.
The researchers found that 11,856 patients experienced MACE in the average 7.1 year follow up period. Patients with resistant hypertension had a 17% increased risk of MACE compared to those with non-resistant hypertension.
When the researchers analysed the risk of different types of cardiovascular events separately they found that compared to patients with non-resistant hypertension, patients with resistant hypertension had a 17% increased risk of stroke and a 34% increased risk of ischaemic stroke but no increased risk of all-cause mortality or acute coronary syndrome.
The study has shown that patients with resistant hypertension have higher risks for cardiovascular events than those with non-resistant hypertension. The elevated risks mainly contribute to increasing stroke events, especially ischaemic stroke.
Subgroup analysis showed that resistant hypertension increased the risks of stroke in females by 35% and in elderly patients by 20%. However, no significant influence was noted in young or male patients.
The finding that resistant hypertension increased the risks of stroke in female and elderly patients, but not in young or male patients, could be because risk factors for cerebral atherosclerosis may differ between genders.
Previous studies have shown that hypertension was the most important risk factor for females to develop cerebral atherosclerosis, compared to diabetes and hypercholesterolemia for males.
While this is the first study to explore the relationship between gender, age, and MACE in patients with resistant hypertension, further research is needed to confirm this relationship and to identify the exact mechanisms involved.
In conclusion, the clinical diagnosis of resistant hypertension should be combined with patient gender and age to provide a more accurate prediction of the risk of stroke. ( Xagena )
Source: European Society of Cardiology, 2014
Durable and potent LDL-cholesterol reduction with Inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Results from a prespecified analysis of pooled data from three phase III studies evaluating the safety and efficacy of Inclisiran,...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
Lorviqua for treatment of adult patients with ALK-positive advanced non-small cell lung cancer, previously treated with one or more ALK tyrosine kinase inhibitors: approved in European Union
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...
Lorlatinib in patients with previously treated ALK+ advanced non-small cell lung cancer: efficacy and safety
Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...
Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...
GLAGOV trial: lowering LDL cholesterol with Evolocumab, a PCSK9 inhibitor, impacts underlying atherosclerotic disease on top of optimized statin therapy
The phase 3 GLAGOV ( GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound )...
Heterozygous familial hypercholesterolemia: 63% of patients treated with Alirocumab no longer required apheresis
Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...
The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor...